<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558023</url>
  </required_header>
  <id_info>
    <org_study_id>5866</org_study_id>
    <nct_id>NCT02558023</nct_id>
  </id_info>
  <brief_title>The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine</brief_title>
  <acronym>Uranic</acronym>
  <official_title>The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate that urapidil is not inferior to nicardipine
      for the treatment of hypertension associated with preeclampsia (PE) and that it is better
      tolerated.

        -  efficacy endpoint : mean arterial blood pressure corrected to 100-120 mmHg after 120 min
           of study drug administration.

        -  safety endpoints : clinical and biological observation for any side effect. All infants
           will be observed in the neonatology unit (during 48h).

      Pharmacokinetic study included to study :

        -  transplacental transfer,

        -  transfer in breast milk,

        -  and neonatal elimination (premature babies of mothers treated with urapidil (less than
           33 WG))
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure at two hours</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Hypertension</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Urapidil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
Maximum dose of 30 mg.h-1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nicardipine : IV
1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
Maximum dose of 6 mg.h-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urapidil</intervention_name>
    <description>Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
Maximum dose of 30 mg.h-1.</description>
    <arm_group_label>Urapidil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>Nicardipine : IV
1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
Maximum dose of 6 mg.h-1</description>
    <arm_group_label>Nicardipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Singleton pregnancy

          -  Patients with remaining hypertension despite an oral treatment for who an iv
             antihypertensive treatment is indicated

        Patient with PE, as defined by :

          -  Systolic Blood Pressure (BP) ≥ 140 mmHg and/or Diastolic BP ≥ 90 mmHg, after the 20th
             week of amenorrhea, without chronic hypertension, AND

          -  Proteinuria &gt; 300 mg.day-1 or &gt; 2 crosses(++) on an urinary dipstick,

        OR

        Patient with severe Pregnancy Induced Hypertension (PIH), as defined by :

        Systolic BP ≥ 160 mmHg and/or Diastolic BP ≥110 mmHg, after the 20th week of amenorrhea,
        without chronic hypertension,

          -  Written informed consent signed and dated by both investigator and patient,

          -  Valid social security affiliation

        Exclusion Criteria:

          -  Known allergy to study drugs

          -  Contra-indication to the study drugs: stenosis of the aortic isthmus, arteriovenous
             shunt, coarctation of the aorta, unstable angina, compensatory hypertension,
             myocardial infarction &lt; 8 days.

          -  Eclampsia

          -  Person with difficulty understanding information

          -  Person with diminished responsibility,

          -  Ongoing intravenous antihypertensive treatment,

          -  No pressure cuff adapted to the morphology of the arms of the patients

          -  Concomitant use of 5 phosphodiesterase inhibitors

          -  Participation in a clinical trial within 6 months prior to inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre DIEMUNSCH, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre DIEMUSCH, PUPH</last_name>
    <phone>33.3.88.12.70.78</phone>
    <email>pierre.diemunsch@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Anesthésie - CMCO</name>
      <address>
        <city>Schiltigheim</city>
        <zip>67303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre DIEMUNSCH, MD.PH</last_name>
    </contact>
    <investigator>
      <last_name>Rita VIZITIU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina FAITOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Anesthésie et de Réanimation Médicale, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre DIMUNSCH, PUPH</last_name>
      <phone>33.3.88.12.70.78</phone>
      <email>pierre.diemunsch@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre DIEMUNSCH, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent GARCIA, CCU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRE-ECLAMPSIA</keyword>
  <keyword>URAPIDIL</keyword>
  <keyword>NICARDIPINE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Urapidil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

